JP2022054483A - Nmn-containing antioxidant composition and method for preparing the same - Google Patents

Abstract

To provide an NMN-containing antioxidant composition and method for producing the same for overcoming the defect of a conventional anti-aging product that has difficulty achieving excellent antioxidant property, anti-aging effect, detoxification to human body, and stability of product quality.SOLUTION: Disclosed are an NMN-containing antioxidant composition that is prepared from a raw material containing 10 to 13 pts.by mass of nicotinamide mononucleotide, 0.02 to 0.06 pts.by mass of coenzyme Q10, 0.2 to 0.5 pts.mass of plasmalogen, 0.8 to 2.0 pts.by mass of nucleic acid, 0.05 to 1 pts.by mass of amino acid, 0.2 to 0.5 pts.by mass of vitamin, and 0.005 to 0.08 pts.by mass of trace element, and a method for preparing the same.SELECTED DRAWING: None

Description

The present invention relates to the technical field of health foods, and specifically to NMN-containing antioxidant compositions and methods for preparing them.

As people's living standards improve, interest in health and longevity grows day by day. At the same time, various types of anti-aging drugs have been continuously on the market, but their effects are different. In addition, as the current social aging problem has become more serious, detailed research on highly effective anti-aging complex drugs will surely help to achieve the goal of "healthy aging".

NAD + (nicotinamide adenine dinucleotide, also known as coenzyme I) is an important coenzyme in the tricarboxylic acid circuit that promotes sugar, fat and amino acid metabolism, is involved in energy synthesis, and is involved in cell metabolism, oxidative reduction and protein. It is an important active substance involved in more than a thousand important physiological reactions such as transcription. However, with aging, NAD + levels continue to decline and cell metabolism is also affected. In the human body, NAD + is synthesized by nicotinamide mononucleotide (NMN), a precursor of NAD + synthesis. In 2013, Professor David Sinclair published a sentence in the "Cell" magazine with the following content: That is, after administration of NMN to mice to increase NAD for one week, 22-month-old mice (corresponding to 60-year-old humans) are completely different from the previous ones, and are major factors such as mitochondrial homeostasis and muscle health. The index showed the same level as the 6-month-old mouse (corresponding to a 20-year-old human), and the life span of the mouse was extended by 20%. Therefore, an NMN-containing anti-aging product has been realized.

Most of the NMN anti-aging products currently on the market are a combination of NMN and some Chinese herbs and can enhance the function of the body to some extent, but the effect of use is not ideal and the anti-aging effect is enhanced. There is a need. To achieve excellent anti-aging effects, some anti-aging products use industrial ingredients with strong antioxidant properties. It is effective in the short term, but long-term use is very harmful to the human body. Vitamin-type antioxidants have been added to some anti-aging products, but the stability of the products is inferior.

Therefore, in order to solve the defects that it is difficult to achieve both excellent antioxidant, anti-aging effect, harm to human body, and stability of product quality of anti-aging products in the prior art, anti-oxidation and anti-aging There is an urgent need for the development of compositions.

The technical problem to be solved by the present invention is to overcome the defect of the conventional anti-aging product that it is difficult to achieve both excellent antioxidant effect, anti-aging effect, detoxification to human body, and stability of product quality. To provide an NMN-containing antioxidant composition and a method for producing the same. It is said that the antioxidant composition provided by the present invention can achieve both excellent antioxidant and anti-aging effects, detoxification to the human body, and stability of product quality by a specific composition, a specific compounding ratio, and a rational formulation. It has advantages, is easy to use, has a good absorption effect, and has no defects or side effects.

That is, the present invention solves the above technical problem by the following solution means.
In the present invention, as active ingredients, 10 to 13 parts by mass of nicotinamide mononucleotide, 0.02 to 0.06 parts by mass of coenzyme Q10, 0.2 to 0.5 parts by mass of plasmalogen, 0.8 to 2 parts by mass. Contains NMN prepared from raw materials containing 0.0 parts by weight of nucleic acid, 0.05 to 1 part by weight of amino acids, 0.2 to 0.5 parts by weight of vitamins and 0.005 to 0.08 parts by weight of trace elements. An antioxidant composition is provided.

Preferably, as the active ingredient, the nicotinamide mononucleotide is 10 to 12.8 parts by mass, for example, 10.64 parts by mass, 12 parts by mass, or 12.8 parts by mass.

Preferably, as the active ingredient, the coenzyme Q10 is 0.028 to 0.06 parts by mass, for example 0.06 parts by mass, 0.048 parts by mass, or 0.026 parts by mass.

Preferably, as the active ingredient, the plasmalogen is 0.24 to 0.45 parts by mass, for example 0.45 parts by mass, 0.24 parts by mass, or 0.26 parts by mass.

Preferably, as the active ingredient, the nucleic acid is 0.92 to 1.92 parts by mass, for example 0.92 parts by mass or 1.92 parts by mass.

Preferably, as the active ingredient, the amino acid is 0.08 to 0.48 parts by mass, for example 0.08 parts by mass, 0.14 parts by mass, or 0.48 parts by mass.

Preferably, as the active ingredient, the vitamin is 0.25 to 0.3 parts by mass, for example 0.26 parts by mass, 0.28 parts by mass, or 0.3 parts by mass.

Preferably, as the active ingredient, the trace element is 0.005 to 0.06 parts by mass, for example 0.00642 parts by mass, or 0.0525 parts by mass.

Preferably, the antioxidant composition comprises 10 to 12.8 parts by mass of nicotine amide mononucleotide, 0.028 to 0.06 parts by mass of coenzyme Q10, 0.24 to 0.45 parts by mass as active ingredients. Plasmalogen, 0.92 to 1.92 parts by mass of nucleic acid, 0.08 to 0.48 parts by mass of amino acids, 0.25 to 0.3 parts by mass of vitamins, 0.005 to 0.06 parts by mass of trace amounts. Prepared from raw materials containing elements.

Preferably, the antioxidant composition comprises 10 to 12.8 parts by mass of nicotine amide mononucleotide, 0.028 to 0.06 parts by mass of coenzyme Q10, 0.24 to 0.45 parts by mass as active ingredients. Plasmalogen, 0.92 to 1.92 parts by mass of nucleic acid, 0.08 to 0.48 parts by mass of amino acids, 0.25 to 0.3 parts by mass of vitamins, 0.005 to 0.06 parts by mass of trace amounts. Prepared from the raw materials of the element.

In the present invention, the origin of the plasmalogen may be chicken breast plasmalogen powder.

Preferably, the nucleic acid comprises RNA and / or DNA. Here, the origin of the DNA may be a salmon milt extract, and the origin of the RNA may be a brewer's yeast extract.

Preferably, the amino acid comprises L-tryptophan and / or L-tyrosine.

Preferably, the vitamin comprises one or more combinations selected from the group consisting of riboflavin (VB2), niacin (VB3), pyridoxine hydrochloride (VB6), vitamin E and vitamin C.

Preferably, the trace element comprises one or more combinations selected from the group consisting of zinc, manganese and selenium. Here, the origin of the zinc may be zinc-containing yeast, and the zinc content in the zinc-containing yeast is preferably 10% by mass. The origin of the manganese may be manganese-containing yeast, and the content of manganese in the manganese-containing yeast is preferably 5% by mass. The origin of the selenium may be selenium-containing yeast, and the content of selenium in the selenium-containing yeast is preferably 0.2% by mass.

In a preferred embodiment of the present invention, the antioxidant composition contains 10.64 parts by mass of NMN, 0.06 parts by mass of Coenzyme Q10, 0.45 parts by mass of plasmalogen, and 0.96 parts by mass as active ingredients. DNA, 0.96 parts by mass RNA, 0.28 parts by mass L-tryptophan, 0.2 parts by mass L-tyrosine, 0.06 parts by mass of riboflavin (VB2), 0.06 parts by mass of niacin, 0.04 parts by mass of pyridoxin hydrochloride, 0.06 parts by mass of vitamin C, 0.06 parts by mass of vitamin E, 0.15 parts by mass of zinc-containing yeast (the zinc content in the zinc-containing yeast is 10 parts by mass). %), 0.15 parts by mass of manganese-containing yeast (the content of manganese in the manganese-containing yeast is 5% by mass), 0.15 parts by mass of selenium-containing yeast (serine in the selenium-containing yeast). Is prepared from raw materials having a content of 0.2% by mass).

In another preferred embodiment of the invention, the antioxidant composition comprises 12 parts by weight NMN, 0.048 parts by weight Coenzyme Q10, 0.24 parts by weight plasmalogen, 0.96 parts by weight as active ingredients. DNA, 0.96 parts by mass RNA, 0.08 parts by mass of L-tryptophan, 0.06 parts by mass of L-tyrosine, 0.04 parts by mass of riboflavin (VB2), 0.06 parts by mass of niacin, 0.04 parts by mass of pyridoxin hydrochloride (VB6), 0.06 parts by mass of vitamin C (L-ascorbic acid P), 0.06 parts by mass of vitamin E, 0.06 parts by mass of zinc-containing yeast (the zinc). The content of zinc in the contained yeast is 10% by mass), 0.06 parts by mass of manganese-containing yeast (the content of manganese in the manganese-containing yeast is 5% by mass), 0.06 parts by mass. It is prepared from a raw material of a selenium-containing yeast (the content of selenium in the selenium-containing yeast is 0.2% by mass).

In another preferred embodiment of the invention, the antioxidant composition comprises 12.8 parts by weight of NMN, 0.028 parts by weight of Coenzyme Q10, 0.26 parts by weight of plasmalogen, 0.46 by weight. Mass of DNA, 0.46 mass of RNA, 0.04 mass of L-tryptophan, 0.04 mass of L-tyrosine, 0.06 mass of riboflavin (VB2), 0.08 mass Niacin, 0.04 parts by mass of pyridoxin hydrochloride (VB6), 0.06 parts by mass of vitamin C (L-ascorbic acid P), 0.06 parts by mass of vitamin E, 0.06 parts by mass of zinc-containing yeast ( The zinc content in the zinc-containing yeast is 10% by mass), 0.06 parts by mass of manganese-containing yeast (the manganese content in the manganese-containing yeast is 5% by mass), 0.06% by mass. It is prepared from the raw material of the selenium-containing yeast (the content of selenium in the selenium-containing yeast is 0.2% by mass).

In the present invention, the raw material of the antioxidant composition may further contain an auxiliary material known in the art, and the auxiliary material is, for example, calcium stearate.

Here, the mass part of the auxiliary material can be set as known in the art, and is, for example, 0.2 to 0.5 parts by mass, or 0.38 parts by mass, as an active ingredient.

In the present invention, the dosage form of the antioxidant composition is a known dosage form in the art, for example, a solid agent or a liquid agent. Here, the solid preparation may be a capsule, a tablet, a pill or a granule, and the liquid preparation may be an oral liquid preparation.

The present invention also provides a method for preparing the antioxidant composition, which comprises a step of mixing the raw materials of the antioxidant composition.

In a preferred embodiment of the invention, the preparation method further comprises the step of separately sieving each of the raw materials of the antioxidant composition prior to mixing, eg, sieving 60 mesh.

In a preferred embodiment of the invention, the preparation method further comprises the steps of separately sieving the dried ingredients on a 60 mesh mesh, then weighing the sieved ingredients at a blending ratio and mixing them uniformly.

In the present invention, the preparation method can further include granulation, drying and sizing according to known steps in the art.

In addition, the preparation method can include a step of producing the antioxidant composition into a solid agent or a liquid agent according to a known process in the art.

A preferred example of the present invention can be obtained by arbitrarily combining the above-mentioned preferable conditions based on the common sense in the art.

All reagents and raw materials used in the present invention are commercially available.

The positive and progressive effects of the present invention are as follows.
1) In the technical means provided by the present invention, nicotinamide mononucleotide (NMN) can play a role in activating the body's energy metabolism and improving the body's oxidative stress response. At the same time, due to the synergistic effect with coenzyme Q10, plasmalogen, nucleic acid, amino acid, vitamin, and trace element, excellent effects such as antioxidant, delayed aging, and improvement of metabolic rate can be obtained, and each component in the composition can be obtained. The structure is stable, and the obtained corresponding product is less likely to be altered or damaged. At the same time, each ingredient is safe and beneficial to the human body, and has the advantages of excellent antioxidant and anti-aging effects, detoxification to the human body, and stability of product quality.

2) In the technical means provided by the present invention, by adopting a specific compounding ratio of a specific component, the combination is rational, the compounding is suitable, easy to use, the absorption effect is good, and defects and side effects are achieved. There is no.

Hereinafter, the technical means in the examples of the present invention will be clearly and completely described, but it is clear that these described examples are not all the examples but only a part of the examples of the present invention. be. Based on the embodiments of the present invention, on the premise of no creative labor, all other embodiments obtained by those skilled in the art should be within the scope of the invention.

Unless otherwise specified, the reagents used in the following examples can be purchased at conventional biochemical reagent stores. Here, NMN was purchased from Yikelai Biotechnology (Shanghai) Co., Ltd. In the example below, the experimental method without specific conditions is selected according to conventional methods and conditions, or product specifications.

In this experiment, the contents of SOD, MDA, and GSH-Px in the liver of the experimental mice were detected to evaluate the modeling status of the mice and the protective effect of the drug.

The T-SOD reagent kit, MDA reagent kit, and GSH-Px reagent kit were all purchased from Nanjing Kensei Biological Company.

Mice are mammals and are the most widely used model organisms for the study of human aging-related mechanisms and the development of anti-aging drugs. Long-term intraperitoneal injection of D-galactose (D-gal) can cause aging of the body. The aging model produced in this way is very similar to the natural aging of the human body. After the aging model is successfully produced, changes in biochemical and physiological indicators of the body are both very similar to natural aging. Therefore, the D-galactose aging model is widely used as the most typical aging research model for studying the aging effect of the body.

Reactive oxygen species (ROS) are compounds containing ROS functional groups produced by the oxidation system and are the most important free radicals in the body. During the body's aging process, the amount of ROS produced is greater than the amount of clearance, and the accumulated ROS damages organs and tissues and accelerates the body's aging.
Superoxide dismutase (SOD) is an active substance derived from a living body, can eliminate harmful substances produced in the living body in a metabolic process, and has a special antiaging effect by supplementing a certain amount of SOD. Bring.
Glutathione peroxidase (GSH-Px) is an important peroxidase-degrading enzyme that is widely present in the body. The active center of GSH-Px is selenocysteine, whose vitality can reflect the body's selenium levels.
Selenium is a composition of the GSH-Px enzyme system that catalyzes GSH to GSSG and reduces toxic peroxides to non-toxic hydroxyl compounds, thereby protecting the structure and function of cell membranes from peroxide damage. ..
Malondialdehyde (MDA) is one of the most important products of membrane lipid peroxidation. Excessive MDA production exacerbates membrane damage and is cytotoxic. Therefore, MDA is an important index for detecting aging.

Both the production and removal of ROS in the aging body are closely related to the liver. In the process of aging, the SOD activity of the liver is significantly reduced and the content of lipid peroxide MDA is increased, so that the liver's ability to remove ROS is reduced, the accumulation of ROS is promoted, and the body ages. Accelerate. The liver is also an important organ for the synthesis of antioxidant enzymes such as glutathione (GSH). Similarly, aging affects the enzymatic activity of GSH.

[Example 1]
Preparation of composition capsule (1) Active raw material: 10.64 g of NMN, 0.6 g of coenzyme Q10 aqueous solution (coenzyme Q10 content is 10% by mass), 0.45 g of plasmalogen, 0.96 g. DNA, 0.96 g RNA, 0.28 g L-tryptophan, 0.2 g L-tyrosine, 0.06 g riboflavin (VB2), 0.06 g niacin, 0.04 g pyridoxine hydrochloride (VB6), 0.06 g of Vitamin C (L-ascorbic acid P), 0.06 g of dried vitamin E, 0.15 g of zinc-containing yeast (zinc content is 10% by mass), 0.15 g of manganese-containing yeast ( Manganese content is 5% by mass), 0.15g selenium-containing yeast (selenium content is 0.2% by mass).
(2) Secondary material: 0.38 g of calcium stearate (3) Preparation method:
After each of the dried raw material and auxiliary material was sieved by 60 mesh, the selected raw material was weighed in the compounding ratio, and at the same time, the related auxiliary material was added and uniformly mixed. After the steps of granulation, drying, granulation and the like, the capsules were filled with known methods to obtain capsules.
For each capsule, the theoretical mass of the content is 260 mg and the theoretical content of NMN is 182 mg.

[Example 2]
Preparation of composition capsules (1) Active raw materials: 12 g of NMN, 0.48 g of coenzyme Q10 aqueous solution (coenzyme Q10 content is 10% by mass), 0.24 g of plasmalogen, 0.96 g of DNA, 0.96 g RNA, 0.08 g L-tryptophan, 0.06 g L-tyrosine, 0.04 g riboflavin (VB2), 0.06 g niacin, 0.04 g pyridoxine hydrochloride (VB6), 0. 06 g of vitamin C (L-ascorbic acid P), 0.06 g of dried vitamin E, 0.06 g of zinc-containing yeast (zinc content is 10% by mass), 0.06 g of manganese-containing yeast (of manganese) The content is 5% by mass), 0.06 g of selenium-containing yeast (the content of selenium is 0.2% by mass).
(2) Secondary material: 0.38 g of calcium stearate (3) Preparation method:
After each of the dried raw material and auxiliary material was sieved by 60 mesh, the selected raw material was weighed in the compounding ratio, and at the same time, the related auxiliary material was added and uniformly mixed. After the steps of granulation, drying, granulation and the like, the capsules were filled with known methods to obtain capsules.
For each capsule, the theoretical mass of the content is 260 mg and the theoretical content of NMN is 200 mg.

[Example 3]
Preparation of composition capsules (1) Active raw materials: 12.8 g NMN, 0.28 g coenzyme Q10 aqueous solution (coenzyme Q10 content is 10% by mass), 0.26 g plasmalogen, 0.46 g. DNA, 0.46 g RNA, 0.04 g L-tryptophan, 0.04 g L-tyrosine, 0.06 g riboflavin (VB2), 0.08 g niacin, 0.04 g pyridoxine hydrochloride (VB6), 0.06 g of Vitamin C (L-ascorbic acid P), 0.06 g of dried vitamin E, 0.06 g of zinc-containing yeast (zinc content is 10% by mass), 0.06 g of manganese-containing yeast ( Manganese content is 5% by mass), 0.06g selenium-containing yeast (selenium content is 0.2% by mass).
(2) Secondary material: 0.38 g of calcium stearate (3) Preparation method:
After each of the dried raw material and auxiliary material was sieved by 60 mesh, the selected raw material was weighed in the compounding ratio, and at the same time, the related auxiliary material was added and uniformly mixed. After the steps of granulation, drying, granulation and the like, the capsules were filled with known methods to obtain capsules.
For each capsule, the theoretical mass of the content is 260 mg and the theoretical content of NMN is 219 mg.

[Comparative Example 1]
NMN + Auxiliary Material Composition The difference from Example 3 is that the composition of the composition is different, and the composition comprises 15.22 g of NMN and 0.38 g of calcium stearate, and the preparation method is the same as that of Example 3. Prepared in.
For each capsule, the theoretical mass of the content is 260 mg and the theoretical content of NMN is 230 mg.

[Test Example 1]
Stability test of composition In the stability investigation test, the capsules obtained in Examples 1 to 3 were placed under long-term storage conditions (30 ° C ± 2 ° C, RH 65% ± 5%) for 12 months. The content of NMN in the pharmaceutical product after 0 months, 1 month, 2 months, 3 months, 6 months and 12 months was measured by chromatography. The chromatographic conditions are as follows.

Column: Welch Ultimate AQ-C18 (5 μm, 4.6 × 250 mm); Buffer: 0.05 mol / L Diammonium hydrogen phosphate: 10% aqueous solution of tetrabutylammonium hydroxide = 91: 1, pH with phosphoric acid 3. Adjusted to 6; mobile phase: acetonitrile: buffer = 8:92; flow velocity: 1.0 mL / min; detection wavelength: 254 nm; column temperature: 30 ° C.; injection volume: 10 μL; execution time: 40 minutes; diluent: ultrapure water Pure water.

The test results are shown in Table 1 below.

From the above test results, the NMN-containing antioxidant compositions prepared in Examples 1 to 3 of the present invention have good pharmaceutical stability, and the NMN content has almost no loss within 0 to 3 months. It turns out that it remains high over the months. It was shown that the preparation method of the examples of the present invention and the synergistic interaction between the raw material components are effective in improving the stability of the NMN and the raw material components in the NMN-containing antioxidant composition.

[Test Example 2]
Measurement of Anti-Aging Effect of Composition The disclosed antioxidant and anti-aging composition formulations were tested in mice to measure their efficacy and safety.

Eighty adult mice were selected, all mice were adaptively reared in the animal room for 2 weeks, and the light was adjusted by a 12-hour daily rhythm. During the breeding period, the mice were allowed to freely ingest food and water, and the breeding environment temperature was maintained at 20 ° C to 22 ° C and the relative humidity was maintained at 50% to 60%.

After a two-week adaptation period, experiments were performed and mice were categorized according to body weight in the normal group, model group (D-gal 100 mg / kg / day, typical dose), and control group (NMN + sub in Comparative Example 1). Material composition 50 mg / kg / day, typical dose), experimental groups 1, 2 and 3 (product compositions prepared in Examples 1, 2 and 3, respectively, used at 50 mg / kg / day, representative. Dosage). There were 20 animals per group.

Model construction: Except for the normal group, 100 mg / kg body weight D-gal is intraperitoneally injected daily into the other groups, and saline is intraperitoneally injected into the normal group at the same dose and method. We continued for a week to build a subacute aging model.

From the 7th week, the corresponding test drug NMN + auxiliary material composition and product composition were orally administered to the control group and the experimental group, respectively, and the doses are as described above. Physiological saline was orally administered to the normal group and the model group at 100 mg / kg body weight, continued for 4 weeks, and at the end of the experiment after 10 weeks, all the experimental mice were allowed to freely drink water and were slaughtered by fasting.

After slaughter of mice, liver tissue is collected, 0.1 g liver tissue is accurately weighed into a 2 mL Ep tube, 0.9 mL precooled saline is added, uniformly slurryed, centrifuged and supernatant. Was collected and dispensed. That is, 10% by mass of homogenate was prepared. First, the protein concentration of the homogenate was measured, and then the contents of T-SOD, MDA, and GSH-Px were strictly measured according to the operation manual of the product specifications of each corresponding reagent kit.

The experimental results are shown in Table 2 below.

note:
Comparison with normal group: # indicates that there is a significant difference (0.01 <P <0.05), and ## indicates that there is a very significant difference (P <0.01).
Comparison with model group: * indicates that there is a significant difference (0.01 <P <0.05), and ** indicates that there is a very significant difference (P <0.01).

As can be seen from the above experimental data, the control group mice treated with NMN + auxiliary material had a higher content of the beneficial factor T-SOD in the liver tissue than the model group as compared with the (1) model group, and the normal group. Close to the level of. In contrast, compared to the model group, the mice in the experimental group treated with the product compositions of Examples 1, 2 and 3 of the present invention had a much higher T-SOD content than the model group. It exceeded the normal group and the control group.
(2) Compared with the model group, the mice in the control group treated with the NMN + auxiliary material composition had a slightly higher GSH-Px content in the liver tissue than the model group. On the other hand, compared with the model group, the experimental group mice treated with the product compositions of Examples 1, 2 and 3 of the present invention had a higher GSH-Px content than the model group and were almost the same. Close to the level of the normal group.
(3) Compared with the model group, the control group mice treated with NMN + auxiliary material had a lower MDA factor content than the model group, whereas the examples of the present invention were compared with the model group. The mice in the experimental group treated with the product compositions 1, 2 and 3 had a lower MDA factor content in the liver tissue than the model group, which was close to the level of the normal group.

As shown from the above experimental results, both the product composition of the present invention and the NMN + auxiliary material composition of Comparative Example 1 produce an antioxidant effect on the liver of aged mice and protect the health of the liver of aged mice. The product composition of the present invention has a better antioxidant effect than the NMN + auxiliary material composition of Comparative Example 1 due to the synergistic effect between the components.

As shown from the above experimental results, both the product composition of the present invention and the NMN + auxiliary material composition of Comparative Example 1 produce an antioxidant effect on the liver of aged mice and protect the health of the liver of aged mice. The product composition of the present invention has a better antioxidant effect than the NMN + auxiliary material composition of Comparative Example 1 due to the synergistic effect between the components.

The present invention can be used for NMN-containing antioxidant compositions and methods for preparing them.

Claims (10)

As active ingredients, 10 to 13 parts by mass of nicotinamide mononucleotide, 0.02 to 0.06 parts by mass of coenzyme Q10, 0.2 to 0.5 parts by mass of plasmalogen, 0.8 to 2.0 parts by mass. NMN characterized by being prepared from raw materials containing 0.05 to 1 part by mass of amino acids, 0.2 to 0.5 parts by mass of vitamins and 0.005 to 0.08 parts by mass of trace elements. Containing antioxidant composition. As an active ingredient, the nicotinamide mononucleotide is 10 to 12.8 parts by mass.
And / or, as an active ingredient, the coenzyme Q10 is 0.028 to 0.06 parts by mass.
And / or, as an active ingredient, the plasmalogen is 0.24 to 0.45 parts by mass.
And / or the nucleic acid comprises RNA and / or DNA.
And / or, as an active ingredient, the nucleic acid is 0.92 to 1.92 parts by mass.
And / or the amino acids include L-tryptophan and / or L-tyrosine.
And / or, as an active ingredient, the amino acid is 0.08 to 0.48 parts by mass.
And / or said vitamins include one or more combinations selected from the group consisting of riboflavin, niacin, pyridoxine hydrochloride, vitamin E and vitamin C.
And / or, as an active ingredient, the vitamin is 0.25 to 0.3 parts by mass.
And / or the trace element contains one or more combinations selected from the group consisting of zinc, manganese, and selenium, the origin of the zinc is preferably zinc-containing yeast, and the zinc-containing yeast. The content of zinc is preferably 10% by mass, the origin of the manganese is preferably manganese-containing yeast, and the content of manganese in the manganese-containing yeast is preferably 5% by mass, and the selenium. Is derived from selenium-containing yeast, and the content of selenium in the selenium-containing yeast is preferably 0.2% by mass.
And / or, as an active ingredient, the trace element is 0.005 to 0.06 parts by mass.
The NMN-containing antioxidant composition according to claim 1, wherein the raw material of the antioxidant composition further contains an auxiliary material. As an active ingredient, the nicotinamide mononucleotide is 10.64 parts by mass, 12 parts by mass, or 12.8 parts by mass.
And / or, as an active ingredient, the coenzyme Q10 is 0.06 parts by mass, 0.048 parts by mass, or 0.026 parts by mass.
And / or, as an active ingredient, the plasmalogen is 0.45 parts by mass, 0.24 parts by mass, or 0.26 parts by mass.
And / or, as an active ingredient, the nucleic acid is 0.92 parts by mass or 1.92 parts by mass.
And / or, as an active ingredient, the amino acid is 0.08 parts by mass, 0.14 parts by mass, or 0.48 parts by mass.
And / or, as an active ingredient, the vitamin is 0.26 parts by mass, 0.28 parts by mass, or 0.3 parts by mass.
And / or, as an active ingredient, the trace element is 0.00642 parts by mass or 0.0525 parts by mass.
And / or, when the raw material of the antioxidant composition further contains an auxiliary material, the auxiliary material is 0.2 to 0.5 parts by mass, and the auxiliary material is 0.38 parts by mass.
And / or, when the antioxidant composition further contains an auxiliary material, the NMN-containing antioxidant composition according to claim 1, wherein the auxiliary material is calcium stearate. 10 to 12.8 parts by mass of nicotinamide mononucleotide, 0.028 to 0.06 parts by mass of coenzyme Q10, 0.24 to 0.45 parts by mass of plasmalogen, 0.92 to 1.92 parts by mass of nucleic acid , 0.08 to 0.48 parts by mass of amino acids, 0.25 to 0.3 parts by mass of vitamins and 0.005 to 0.06 parts by mass of trace elements. Item 2. The NMN-containing antioxidant composition according to Item 1. 10 to 12.8 parts by mass of nicotinamide mononucleotide, 0.028 to 0.06 parts by mass of coenzyme Q10, 0.24 to 0.45 parts by mass of plasmalogen, 0.92 to 1.92 parts by mass of nucleic acid , 0.08 to 0.48 parts by mass of amino acids, 0.25 to 0.3 parts by mass of vitamins and 0.005 to 0.06 parts by mass of trace elements. The NMN-containing antioxidant composition according to 1. 10.64 parts by mass NMN, 0.06 parts by mass of Coenzyme Q10, 0.45 parts by mass of plasmalogen, 0.96 parts by mass of DNA, 0.96 parts by mass of RNA, 0.28 parts by mass of L- Tryptophan, 0.2 parts by mass L-tyrosine, 0.06 parts by mass of riboflavin, 0.06 parts by mass of niacin, 0.04 parts by mass of pyridoxin hydrochloride, 0.06 parts by mass of vitamin C, 0.06 Vitamin E by mass, 0.15 parts by mass of zinc-containing yeast containing 10% by mass zinc, 0.15 parts by mass of manganese-containing yeast containing 5% by mass of manganese, and 0.15 by mass containing 0.2% by mass of selenium. Prepared from raw materials of selenium-containing yeast by mass,
Alternatively, 12 parts by mass of NMN, 0.048 parts by mass of coenzyme Q10, 0.24 parts by mass of plasmalogen, 0.96 parts by mass of DNA, 0.96 parts by mass of RNA, 0.08 parts by mass of L- Tryptophan, 0.06 parts by mass L-tyrosine, 0.04 parts by mass of riboflavin, 0.06 parts by mass of niacin, 0.04 parts by mass of pyridoxin hydrochloride, 0.06 parts by mass of vitamin C, 0.06 Vitamin E by mass, 0.06 parts by mass of zinc-containing yeast containing 10% by mass, 5% by mass of manganese containing 0.06 parts by mass of manganese-containing yeast, and 0.2% by mass of selenium. Prepared from 0.06 parts by weight of selenium-containing yeast raw material containing
Alternatively, 12.8 parts by mass of NMN, 0.028 parts by mass of Coenzyme Q10, 0.26 parts by mass of plasmalogen, 0.46 parts by mass of DNA, 0.46 parts by mass of RNA, 0.04 parts by mass of RNA. L-tryptophane, 0.04 parts by mass L-tyrosine, 0.06 parts by mass of riboflavin, 0.08 parts by mass of niacin, 0.04 parts by mass of pyridoxin hydrochloride, 0.06 parts by mass of vitamin C, 0 .06 parts by mass of Vitamin E, 0.06 parts by mass of zinc-containing yeast containing 10% by mass of zinc, 5% by mass of manganese-containing 0.06 parts by mass of manganese-containing yeast, and 0.2% by mass of selenium. The NMN-containing antioxidant composition according to claim 1, wherein the NMN-containing antioxidant composition is prepared from a raw material of 0.06 parts by mass of a selenium-containing yeast containing the above. The dosage form of the antioxidant composition is a solid or a liquid, the solid is preferably a capsule, tablet, pill or granule, and the liquid is preferably an oral liquid. The NMN-containing antioxidant composition according to claim 1. The method for preparing an antioxidant composition according to any one of claims 1 to 7, further comprising a step of mixing the raw materials of the antioxidant composition. The preparation method further comprises the steps of separately sieving each of the raw materials of the antioxidant composition prior to mixing, eg, sieving 60 mesh.
And / or said preparation method further comprises granulation, drying and sizing.
The method for preparing an antioxidant composition according to claim 8, further comprising a step of producing the antioxidant composition into a solid agent or a liquid agent. The method of claim 8 further comprises a step of separately sieving the dried raw materials on a 60-mesh sieve, then weighing the selected raw materials in a blending ratio and uniformly mixing them. Method for preparing antioxidant composition.